|
|
|
|
| LEADER |
01673nam a2200313 u 4500 |
| 001 |
EB001999640 |
| 003 |
EBX01000000000000001162541 |
| 005 |
00000000000000.0 |
| 007 |
tu||||||||||||||||||||| |
| 008 |
210907 r ||| eng |
| 245 |
0 |
0 |
|a Clinical review report: Cyclosporine (VERKAZIA) (Santen Canada Inc.)
|h Elektronische Ressource
|b indication : treatment of severe vernal keratoconjunctivitis in children from four years of age through adolescence
|
| 246 |
3 |
1 |
|a Clinical review report for Cyclosporine (Verkazia)
|
| 246 |
3 |
1 |
|a Cyclosporine (VERKAZIA) (Santen Canada Inc.)
|
| 250 |
|
|
|a Version: final (with redactions)
|
| 260 |
|
|
|a Ottawa (ON)
|b Canadian Agency for Drugs and Technologies in Health
|c 2020, January 2020
|
| 300 |
|
|
|a 1 PDF file (68 pages)
|b illustrations
|
| 505 |
0 |
|
|a Includes bibliographical references
|
| 653 |
|
|
|a Child
|
| 653 |
|
|
|a Canada
|
| 653 |
|
|
|a Conjunctivitis, Allergic / drug therapy
|
| 653 |
|
|
|a Adolescent
|
| 653 |
|
|
|a Cyclosporine / therapeutic use
|
| 710 |
2 |
|
|a Canadian Agency for Drugs and Technologies in Health
|
| 041 |
0 |
7 |
|a eng
|2 ISO 639-2
|
| 989 |
|
|
|b NCBI
|a National Center for Biotechnology Information
|
| 490 |
0 |
|
|a CADTH common drug review
|
| 856 |
4 |
0 |
|u http://www.ncbi.nlm.nih.gov/books/NBK558360
|3 Volltext
|n NLM Bookshelf Books
|3 Volltext
|
| 082 |
0 |
|
|a 610
|
| 520 |
|
|
|a The objective of this CADTH Common Drug Review (CDR) report is to perform a systematic review of the beneficial and harmful effects of 0.1% cyclosporine topical ophthalmic emulsion administered as one drop four times a day for the treatment of severe vernal keratoconjunctivitis in children from four years of age through adolescence
|